NEW YORK (GenomeWeb News) – Asuragen said today that it will work with Biogen Idec to develop a companion diagnostic test for a cancer drug.

Asuragen will use its RNA technologies to develop an assay that could help select which patients will benefit from a drug candidate that Biogen Idec now has in clinical development.

The Austin, Texas-based Asuragen currently offers its Signature Genetic Testing and Oncology Testing product lines, as well as its Armored RNA technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.